Circulating Biomarker in Malignant Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 5307
Special Issue Editor
Interests: melanoma; uveal melanoma; circulating tumor cells; circulating tumor DNA; exosomes; platelets; immunotherapy; targeted therapy; genetic evolution; drug resistance; single cell-sequencing
Special Issue Information
Dear Colleagues,
Current protocols for prognostication, prediction, and monitoring of therapy response and relapse in melanoma patients often rely on invasive tumor biopsies, which provide valuable information on a single tumor at a single time point. There is an unmet need for blood-based tests to guide treatment decisions and monitoring of melanoma patients. This is particularly important as new adjuvant and neoadjuvant regimes are entering clinical practice.
Analysis of tumor biomarkers, such as circulating tumor DNA, circulating tumor cells, and tumor-derived extracellular vesicles, provides a window into features of the melanoma lesions that can inform patients' treatment and clinical management.
This Special Issue of Cancers aims to highlight new findings in the potential role of circulating biomarkers in enabling timely and accurate diagnosis, treatment, and assessment of therapeutic response in melanoma patients. We look forward to receiving manuscripts highlighting novel contributions to this rapidly evolving translational research field essential to improving melanoma outcomes.
Prof. Dr. Elin S. Gray
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- circulating tumor cells
- circulating tumor DNA
- exosomes
- platelets
- immunotherapy
- targeted therapy
- genetic evolution
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.